MRNA · CIK 1682852
What Moderna, Inc. told the SEC could break it.
Moderna's disclosures center on the fragility of an mRNA supply chain and a concentrated, shrinking customer base. It depends on raw materials and excipients that are often single-source, new to the pharmaceutical industry, used in novel ways, and in some cases not yet scaled for commercial supply, so a manufacturing failure or shortage could delay or interrupt its products. Its revenue comes from a small number of governments, distributors, and organizations each above 10% of total revenue — concentration that matters more as product revenue has fallen from $6.8 billion in 2023 to $1.9 billion in 2025 — and its commercialization hinges on optimizing new manufacturing plants in Australia, Canada, and the U.K. plus reliance on third parties for manufacturing, testing, and distribution.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source, novel raw materials and excipients not yet scaled to commercial supplyhigh
Moderna uses a number of raw materials and excipients that may have a single source of supply, are new to the pharmaceutical industry and are employed in a novel manner — some not yet scaled to commercial supply — so unexpected manufacturing/testing failures or shortages could delay or interrupt clinical and commercial supply of its mRNA products.
“We utilize a number of raw materials and excipients that may have a single source of supply, are new to the pharmaceutical industry and are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures or supply shortages.”
SEC filing →As of 2026
Customer concentration
- concentration in customers each >10% of revenue (governments/distributors)medium
A significant portion of Moderna's revenue is generated from a small number of entities (wholesalers/distributors, governments and organizations) that each accounted for more than 10% of total revenue and accounts receivable — concentrating revenue and collection risk as its overall product revenue has fallen sharply (from $6.8B in 2023 to $1.9B in 2025).
“A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:”
SEC filing →As of 2026
Other disclosures
- global manufacturing-network optimization (new AU/CA/UK plants) and third-party manufacturing reliancemedium
Moderna's commercialization depends on facilities producing at commercial scale/yield; its new manufacturing plants in Australia, Canada and the UK carry operating risk, and it may rely on third parties for manufacturing, packaging, testing, warehousing, distribution and raw-material supply — arrangements it must secure on favorable terms to develop, manufacture and distribute products.
“Our new manufacturing plants in Australia, Canada and the United Kingdom are subject to risks associated with operating these facilities, and we may encounter difficulties in optimizing our global manufacturing network. To supplement our internal manufacturing infrastructure, we may rely on third parties for product manufacturing, packaging, testing, warehousing, distribution and other logistical services, and the manufacture and testing of raw materials, components, parts and consumables.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Vertex Pharmaceuticals Incorporated
“Collaboration Revenue by Strategic Collaborator: 2025 2024 2023 Vertex $ 13 $ 23 $ 82 Other — 25 1 Total collaboration revenue $ 13 $ 48 $ 83”
Cited →“Under the terms of the Moderna Settlement Agreement, Moderna will make an aggregate $950.0 million Noncontingent Settlement Payment to us and Genevant on or before July 8, 2026.”
Cited →Recordati S.p.A.
“In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch